Drug Clinical Trials List

Display 471 - 480 from 730

Study Title	Study Sponsor	Status	Study Drug	Trial Phase	Study Protocol Number	Site
Post-authorization safety study in patients with type 2 diabetes mellitus to assess the incidence of ketoacidosis, severe complications of urinary tract infection, volume depletion, and dehydration among patients treated with EMPAGLIFLOZIN or DPP-4 inhibitors in Saudi Arabia	Boehringer Ingelheim	Ongoing	Jardiance	4	1245/149	Armed Force Hospital (Al-Hada), King Fahad Medical City (Riyadh)
MultiZonal obsERvational study conducted By clinIcal practitioners on Repatha® use iN subjects with hyperlipIdemia - ZERBINI	Amgen	Ongoing	Repatha	4	2016.03.27	Saud Al-Babtain Cardiac Center (Dammam), King Fahd Military Medical Complex (Dhahran), King Khalid University Hospital (Riyadh), King Abdulaziz University Hospital (Jeddah), Armed Force Hospital (Taif), Armed Force Hospital (Khamis Mushait), Prince Sultan Cardic Center (Riyadh)
A single-arm interventional Phase IV, post-authorisationstudy evaluating the safety of pediatric patients withtransfusional hemosiderosis treated with deferasiroxcrushed film coated tablets	Novartis	Ongoing	Deferasirox	4	CICL670F24	King Abdulaziz Medical City NG (Jeddah)
AURIGA / An observationAl stUdy pRogram toInvestiGate the effectiveness of intravitreal Aflibercept indiabetic macular edema and/or macular edema secondary toretinal vein occlusion in a real world setting.	Bayer	Ongoing	Aflibercept	4	19157	King Faisal Specialist Hospital and Research Center (Riyadh), King Faisal Specialist Hospital and Research Center (Jeddah), King Khalid University Hospital (Riyadh), King Khaled Eye Specialist Hospital (Riyadh)
Adjunct Low Dose Ketamine Infusion Versus Standard of Care in Mechanically Ventilated Critically Ill Patients at a Tertiary Saudi Hospital (ATTAINMENT Trial): Randomized, Prospective, Pilot Trial	King Faisal Specialist Hospital & Research Center	Ongoing	Ketamine	3	2191187	King Faisal Specialist Hospital and Research Center (Riyadh)
"A Phase 3, Multicenter, Double-blind, Randomized, Placebo-controlledClinical Study to Evaluate the Safety and Efficacy of Ertugliflozin (MK-8835/PF-04971729)in Pediatric Participants (ages 10 to 17 years, inclusive) with Type 2 Diabetes Mellitus"	MSD	Ongoing	Ertugliflozin	3	MK-8835-059-00	King Salman Hospital (Riyadh), King Abdulaziz Medical City NG (Jeddah), King Fahad Medical City (Riyadh)
Carvedilol in Preventing Cardiac Toxicity in Patients With Metastatic HER-2-Positive Breast Cancer	SWOG (Southwest Oncology Group)	Ongoing	CARVEDILOL	3	S1501	King Faisal Specialist Hospital and Research Center (Riyadh)
A Randomized, Multicenter, Open-Label, Phase 3 Study to Compare the Efficacy and Safety of Acalabrutinib (ACP-196) in Combination with Venetoclax with and without Obinutuzumab Compared to Investigator’s Choice of Chemoimmunotherapy in Subjects with Previously Untreated Chronic Lymphocytic Leukemia Without del(17p) or TP53 Mutation	Acerta Pharma BV	Ongoing	Acalabrutinib	3	D8221C00001	King Fahad Specialist Hospital (Dammam)
"A Phase III Double-blind Randomised Study Assessing the Efficacy andSafety of Capivasertib + Paclitaxel Versus Placebo + Paclitaxel as First-lineTreatment for Patients with Histologically Confirmed, Locally Advanced(Inoperable) or Metastatic Triple-Negative Breast Cancer (TNBC)"	AstraZeneca	Ongoing	Capivasertib	3	D3614C00001	King Fahad Specialist Hospital (Dammam), King Abdullah Medical City (Makkah), Specialized Medical Center (Riyadh)
AN OPEN-LABEL STUDY OF RISDIPLAM IN INFANTS WITH GENETICALLY DIAGNOSED AND PRESYMPTOMATIC SPINAL MUSCULAR ATROPHY	Roche	Terminated	Risdiplam	2	BN40703	King Faisal Specialist Hospital and Research Center (Riyadh)